Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Yondelis
Trabectedin is an antineoplastic agent derived from the marine organism Ecteinascidia turbinata. It exerts its anticancer activity by binding to the minor groove of DNA, interfering with transcription and DNA repair mechanisms, ultimately leading to cell cycle arrest and apoptosis. Trabectedin is primarily used in the treatment of advanced soft tissue sarcoma and ovarian cancer.
For the treatment of advanced soft tissue sarcoma and ovarian cancer.
Hepatotoxicity, including severe and fatal hepatic failure, has been reported. Myelosuppression, including neutropenia, thrombocytopenia, and anemia, has been reported. Rhabdomyolysis has been reported.
Outcome:
Reduced trabectedin efficacy
Mechanism:
Induction of CYP3A4
Outcome:
Increased risk of bleeding
Mechanism:
Pharmacodynamic interaction
Outcome:
Reduced trabectedin absorption
Mechanism:
Chelation
Most likely new formulation: Liposomal trabectedin (2025, 60% confidence)
Based on current usage trends and clinical trial data, there is a 70% likelihood of trabectedin being approved for additional cancer indications within the next 5 years.
Antineoplastic, Alkylating agent
Tetrahydroisoquinoline alkaloid